# EDGAR Filing Document

**Accession Number:** 0001526119
**File Stem:** 0000000000-23-003284
**Filing Date:** 2023-3
**Character Count:** 7000
**Document Hash:** 8e2a7297a5b1408b48efbfea050775e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-003284.hdr.sgml**: 20230522

**ACCESSION NUMBER**: 0000000000-23-003284

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230331

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Verastem, Inc.
- **CENTRAL INDEX KEY:** 0001526119
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 273269467
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 117 KENDRICK STREET
- **STREET 2:** SUITE 500
- **CITY:** NEEDHAM
- **STATE:** MA
- **ZIP:** 02494
- **BUSINESS PHONE:** (781) 292-4200

**MAIL ADDRESS:**
- **STREET 1:** 117 KENDRICK STREET
- **STREET 2:** SUITE 500
- **CITY:** NEEDHAM
- **STATE:** MA
- **ZIP:** 02494
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-23-036106

## Text-Extract

```

United States securities and exchange commission logo

                             March 31, 2023

       Brian Stuglik
       Chief Executive Officer
       Verastem, Inc.
       117 Kendrick Street, Suite 500
       Needham, MA 02494

                                                        Re: Verastem, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed March 23,
2023
                                                            File No. 333-270794

       Dear Brian Stuglik:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comment. In our comment, we may ask you to provide us
with information so
       we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Registration Statement on Form S-3 filed March 23, 2023

       General

   1.                                                   Question 139.11 of our
Securities Act Sections Compliance and Disclosure Interpretations
                                                        details the
circumstances under which the issuance of a convertible security meets the
                                                        conditions under which
a company may file a registration statement for the resale of
                                                        privately placed
securities before their actual issuance and states that closing conditions
                                                        relating to the market
price of the company   s securities are unacceptable conditions. Here,
                                                        in relation to the
second tranche of shares to be registered we note a closing condition
                                                        relating to the shares'
market price. Please provide us with a detailed analysis to support
                                                        your conclusion that
registration of the second tranche is appropriate at this time.

                                                        We remind you that the
company and its management are responsible for the accuracy
 Brian Stuglik
Verastem, Inc.
March 31, 2023
Page 2

and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Jason Drory at 202-551-8342 or Laura Crotty at
202-551-7614 with any
other questions.

                                                           Sincerely,
FirstName LastNameBrian Stuglik
                                                           Division of
Corporation Finance
Comapany NameVerastem, Inc.
                                                           Office of Life
Sciences
March 31, 2023 Page 2
cc:       Thomas J. Danielski
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 31, 2023

Brian Stuglik  
Chief Executive Officer  
Verastem, Inc.  
117 Kendrick Street, Suite 500  
Needham, MA 02494

**Re: Verastem, Inc.  
Registration Statement on Form S-3  
Filed March 23, 2023  
File No. 333-270794**

Dear Brian Stuglik:

We have limited our review of your registration statement to those issues we have addressed in our comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments.

Registration Statement on Form S-3 filed March 23, 2023

# General

1. Question 139.11 of our Securities Act Sections Compliance and Disclosure Interpretations details the circumstances under which the issuance of a convertible security meets the conditions under which a company may file a registration statement for the resale of privately placed securities before their actual issuance and states that closing conditions relating to the market price of the company’s securities are unacceptable conditions. Here, in relation to the second tranche of shares to be registered we note a closing condition relating to the shares’ market price. Please provide us with a detailed analysis to support your conclusion that registration of the second tranche is appropriate at this time.

We remind you that the company and its management are responsible for the accuracy

Brian Stuglik
Verastem, Inc.
March 31, 2023
Page 2

and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Please contact Jason Drory at 202-551-8342 or Laura Crotty at 202-551-7614 with any other questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Thomas J. Danielski